NCT04808570 - A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2021

Primary Completion Date

November 22, 2023

Study Completion Date

November 22, 2023

Conditions

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG

TQ-B3525 tablets

TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.

Trial Locations (9)

Jiangsu Province Hospital, Nanjing

Tianjin Medical University General Hospital, Tianjin

The Second Xiangya Hospital of Central South University, Changsha

The First Affiliate Hospital of Guangzhou Medical University, Guangzhou

Guangzhou First People's Hospital, Guangzhou

The First Affiliated Hospital of Guangxi Medical University, Nanning

The Affiliated Hospital of Guizhou Medical University, Guiyang

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

Tianjin Medical University Cancer Institute & Hospital, Tianjin